Learn about AREXVY, the first RSV vaccine FDA-approved for the prevention of lung and lower airway infection for both adults aged 60+ years and those in their 50s at increased risk.

Arexvy (abbreviation: RSVPref3) is a vaccine given to prevent severe RSV disease. CDC recommends RSV vaccines, including Arexvy, for: When is Arexvy given? • As a single, one-time 0.5 mL …

Jun 19, 2025 · Arexvy is a vaccine used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD, lung infections) in adults 60 years and older, and adults aged 50 through 59 …

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older.

Jun 7, 2024 · GSK announced FDA approval of AREXVY Vaccine to prevent LRTD in adults aged 50-59 at heightened risk.

Jun 16, 2024 · Arexvy was the first vaccine approved to prevent respiratory syncytial virus (RSV). RSV is a common virus that usually causes mild cold-like symptoms. These symptoms can be more severe …

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: individuals 50 through 59 years of …

Jun 16, 2023 · Arexvy is a vaccine used to protect adults 60 years of age and older against lower respiratory tract disease (LRTD, diseases of the lungs such as bronchitis or pneumonia) caused by …

Jul 5, 2024 · AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). CDC recommends a …